Oral Care Drives OTC Sales As Glaxo Buffs Its Consumer Health Shine
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
GlaxoSmithKline consumer health sales grow 3% at constant exchange rates during the second quarter driven by Sensodyne oral care and medicated skin care products. CEO Emma Walmsley dismisses rumors of divesting the business, saying firm continues to see “very good potential for growth and performance” of consumer health.
You may also be interested in...
Five Reasons Why GSK Spinning Off Consumer Is Not So Straightforward
GSK once again provided grist to the stock market rumor mill over the weekend, with reports emerging that its chairman has been talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.
Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market
After announcing the $13bn acquisition of Novartis' 36.5% share of their JV, GSK said its Horlicks nutritional beverage line and its consumer health subsidiary in India, the source of most Horlicks sales, are potential divestments. The firm also will consider selling other consumer health nutrition products.
Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market
After announcing the $13bn acquisition of Novartis' 36.5% share of their JV, GSK said its Horlicks nutritional beverage line and its consumer health subsidiary in India, the source of most Horlicks sales, are potential divestments. The firm also will consider selling other consumer health nutrition products.